



## **Peter Tassiopoulos Appointed Chief Operating Officer at Biosign Technologies**

**TORONTO, ONTARIO, Tuesday, July 21, 2009** – Biosign Technologies Inc. (CNSX: **BIO**) today announced the appointment of Mr. Peter Tassiopoulos as Chief Operating Officer. In this role, Mr. Tassiopoulos will set and manage the overall strategy and direction for Biosign, focusing on strategic planning, marketing & sales, operations and capitalization requirements.

Commenting, President Radu Leca said: “Peter is a performance driven executive with a proven ability to exceed business development and revenue generation goals in fluid and complex environments. He has established global distribution networks and alliances with some of the most recognized global enterprises in healthcare. We look forward to working with Peter to sharpen Biosign focus on meeting clear and present market demands, in a disciplined and expeditious manner.”

Peter is a recognized expert in digital health technology commercialization. He has served recently on prestigious panels, such as ‘Mobile Health Management’ and ‘Confronting the Diseases of Poverty to Meet the Millennium Development Goals’ at the United Nations and has been a speaker at numerous healthcare events both in North America and Europe.

“More and more government, industry and consumers have been looking to technology to alleviate the overburdened, understaffed and under funded Healthcare system of today. I believe that Biosign technologies can have a substantial positive impact on these issues while providing unsurpassed quality and safety for all stakeholders involved. This is a very exciting opportunity and I am looking forward to assisting Biosign execute their commercialization plans” stated Peter Tassiopoulos.

Contact:

Radu Leca, President & CEO

Biosign Technologies Inc.

Phone: (416) 218-9800 ext. 234

Email: [ceo@biosign.com](mailto:ceo@biosign.com)

## ***About Biosign Technologies Inc.***

Biosign provides technologies, products and initiatives to address critical problems in global health care. The focus is on monitoring health status, outcomes, and risk toward maximizing clinical awareness, readiness, and effectiveness. The thrust is on enabling autonomous medical care to optimize healthcare quality, access, and cost. The core technology expands virtual instrumentation with universal measurement and rapid knowledge formation to support service oriented enterprising across global markets. Trademarked UFIT, the web-based technology powers several business lines in self-care, wellness, remote patient monitoring, and chronic disease evaluation and management. Key applications include intelligent systems for noninvasive monitoring of common health risks such as high blood pressure, high blood glucose, and adverse responses to medication. For more information on Biosign please visit <http://www.biosign.com>

**The CNSX has neither approved nor disapproved the contents of this press release.**

*THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR  
FOR DISSEMINATION IN THE UNITED STATES*

Certain information regarding the Company including management's assessment of future plans and operations, may constitute forward-looking statements under applicable securities laws and necessarily involve risks associated with medical technology companies, research and development, volatility of prices, currency fluctuations, imprecision of estimates, business environment risks, access to labor and services, competition from other companies and ability to access sufficient capital. As a consequence, actual results may differ materially from those anticipated in any forward-looking statements. The Canadian National Stock Exchange (CNSX) does not accept responsibility for the adequacy or accuracy of this release.